$CACI

(CACI) CACI International Now Expects Fiscal 2027 Revenue Range $10.7B-$10.9B, vs. FactSet Est of $10.77B

CACI International updated its fiscal 2027 revenue guidance to $10.7B-$10.9B, slightly below FactSet's estimate of $10.77B. The company's stock has seen a 17% increase year-to-date.

Original reporting
Published Oct 21, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CACI
Neutral
high confidence
Mentioned
$CACI
Relevance
8/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$CACINeutralMed
01

Why it matters

The guidance provides fresh data for valuation models; analysts will adjust target prices accordingly.

02

Market read

New guidance for a mid‑cap defense contractor; modest trading relevance.

03

What to watch

Potential contract wins or cost‑saving initiatives not disclosed could lift actual results above the upper bound.

Relevance 8/10Novelty 8/10Timing: post‑market release

Background

The article repeats CACI's internal rating composites and ESG scores but the actionable element is the newly released FY2027 revenue guidance.

Company-level read

Ticker impact

$CACINeutralHigh confidence
Context

CACI International issued its FY2027 revenue guidance of $10.7B‑$10.9B, a new primary disclosure that differs from the FactSet consensus of $10.77B.

Expected impact

likely modest pressure as the market prices in the guidance range

Evidence & confidence

The revenue range is the first report of FY2027 guidance; the numbers are close to estimates, so price reaction is expected to be muted.

Market effects

Defense and government‑contract services may see slight re‑rating as CACI's guidance informs sector earnings expectations.

U.S. equities may experience minor downward pressure in related defense stocks.

Limited; impact confined to U.S. listed defense contractors.

Counterpoint

If investors focus on the upper end of the range, they may view the guidance as a bullish signal and buy on perceived upside.

Key entities

  • CACI International

    U.S. defense and IT services contractor.

Related articles

$CACIHighAI 8/10

CACI International Inc (CACI) (Q1 2027) Earnings Call Highlights: Record

CACI International reported Q1 2027 earnings with 2.1% organic growth, citing supply chain constraints and budget uncertainty. CEO John Mengucci highlighted a clear strategy and disciplined execution. The company expects stronger growth in the second half, supported by funded backlog growth and recent awards. Integration of acquisitions like ARKA is affecting revenue recognition timing. CACI manages 1,900 programs with varying margins and focuses on long-term investments.

$CACIHighAI 8/10

CACI (CACI) Q1 2027 Earnings Call Transcript

CACI reported Q1 2027 revenue growth of 8%, EBITDA margin of 13.3%, and adjusted EPS increase of 12%. The company generated $133M in free cash flow and won $4.8B in awards. CACI raised its full-year guidance, citing strong demand for its technology, particularly in electronic warfare and space domains. The company is investing in manufacturing capacity to meet demand.

$CACIMed

What CACI International (CACI) Said on Its Q1 Earnings Call

CACI International reported Q1 earnings, highlighting new contracts like Apollo and SOFETOPS 2, and demand for electronic warfare and counter-UAS systems. The company expects to complete Space Development Agency Tranche 1 deliveries this year. CACI opened a new manufacturing center and plans to reduce leverage to 3x by March 2027. Management expressed confidence in the outlook despite a sluggish funding environment.

$CACIHighAI 8/10

CACI Q1 FY27 slides: margin expansion drives guidance raise

CACI International reported Q1 FY27 revenue of $2.47B, up 8.2% YoY but below estimates. EBITDA margin expanded to 13.3%, and EPS beat estimates by 17%. The company raised its FY27 guidance, citing strong profitability and margin expansion. Shares rose 3% premarket. According to CACI, the new guidance reflects improved business visibility and strategic investments.

$CACIMedAI 8/10

CACI (NYSE:CACI) misses Q3 CY2026 sales expectations

CACI reported Q3 CY2026 revenue of $2.47B, missing estimates by 1.4% but beating on adjusted EPS ($7.66 vs $6.60). Adjusted EBITDA also exceeded expectations. The company raised full-year revenue and EPS guidance. Operating margin was steady, but free cash flow margin declined. Backlog remained unchanged at $34B.